https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29771 P<0.0001). Delayed response post first scan was seen in 2 out of 37 (5%) deemed progressive (PD) by RECIST and 2 out of 14 (14%) deemed PD by irRC. Modified CHOI criteria showed response of 38% (14 out of 37). Change in tumour size and density on first follow-up assessment was associated with OS with each 1000 mm² increase in tumour size from baseline increasing the hazard of dying by 25.9% (HR=1.259, (95% CI=1.116-1.420), P=0.0002). Similarly, each 20HU increase in density increased the HR by 15% (HR=1.15, (95% CI 1.045-1.260), P=0.004). Response defined by any criteria had superior OS (CHOI P=0.0084; mCHOI P=0.0183; irRC P<0.0001 and RECIST P=0.0003). Conclusions: Response by any criterion was prognostic. Novel patterns of response and changes on treatment in tumour density suggest complex anti-tumour responses to immunotherapy.]]> Wed 11 Apr 2018 12:06:49 AEST ]]> Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30091 Wed 11 Apr 2018 12:04:08 AEST ]]> Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7958 Sat 24 Mar 2018 08:34:56 AEDT ]]>